Identifying potential therapeutic drug targets and validating their suitability is a complex process involving numerous experimental platforms, including DNA sequence analysis.  Since its introduction in 2005 next-generation sequencing (NGS) has fundamentally altered genomics research.  Large knowledge-gaining experiments are in progress that were financially unjustifiable or even  impossible five years ago.  These include metagenomics to compare different disease states or patient variablility, genome sequencing of model and pathogenic species or ELT compound library screening techniques.

NGS is now successfully utilised by biopharmaceutical companies from the earliest stages of drug discovery to provide detailed genomic data and clinical applications are now emerging.  These range from investigating the molecular basis of drug resistance and planning antimicrobial regimens, to vaccine development and disease diagnostics.  In the rapidly growing field of personalised medicine, eight percent of medicines now have a biomarker or stratified element as compared to just a few percent five years ago.

As sequencing costs continue to fall, the future will see even faster identification of responders and non-responders, benefiting patients, prescribers and payors.

Production for the event is now underway. To discuss the progam or speak at the meeting please contact This e-mail address is being protected from spambots. You need JavaScript enabled to view it .

For sponsorship and exhibition opportunities please contact This e-mail address is being protected from spambots. You need JavaScript enabled to view it .

Why should you attend this event?

Join us for two days of insights and case studies from leading experts and industry executives, enabling you to:

• Generate longer nucleic acid and oligonucleotide sequences of higher quality
• Increase consensus accuracy and genome coverage
  
• Maximise the alignment and assembly of NGS reads with reference sequences
  
• Enhance signal-to-noise measurements in real-time sequencing
  
• Utilise exomics to elucidate gene families implicated in disease or pharmacogenetic effects
• Improve mapping in repetitive regions when resequencing
• Catalogue the transcriptomes of cells, tissues and pathogens
• Perform quantitative applications more effectively with third generation platforms
• Clarify analysis requirements prior to epigenomic studies

Hear keynote addresses from:

• Benjamin Sidders, Principal Scientist, Bioinformatician, Pfizer
• Wilhelm Ansorge, Visiting Professor, École Polytechnique Fédérale de Lausanne

Our expert speaker line-up also includes:

• Nicholas Murgolo, Fellow, Merck Research Laboratories
  
• Guy Cochrane, European Nucleotide Archive Team Leader, European Bioinformatics Institute
  
• John Marioni, Group Leader, European Bioinformatics Institute
  
• Michael Quail, Sequencing R&D Team Leader, The Wellcome Trust Sanger Institute
  
• Lisa Crossman, Microbial Genomes Project Leader, The Genome Analysis Centre
  
• Nicolas Fischer, Head of Research, NovImmune
• Lachlan Coin, Senior Lecturer in Statistical Genomics, Imperial College London
  
• Reiner Schulz, RCUK Research Fellow in Functional Genomics, King’s College London
  
• Guy Barker, Director, Genomics Resource Centre, University of Warwick
  
• Patrick Descombes, Head of Functional Genomics Core, Nestlé Institute of Health Sciences
  
• Irena Zaharieva, Clinical Research Associate, University College London
  
• Jian Han, Faculty Investigator, HudsonAlpha Institute for Biotechnology
  
• Alessandra Ferlini, Professor in Medical Genetics, University of Ferrara
  
• Mat Upton, Senior Lecturer in Medical Microbiology, University of Manchester
  
• Richard Bax, Senior Partner, TranScrip Partners
  
• Sterghios Moschos, Reader in Industrial Biotechnology, University of Westminster
  
• Lori Snyder, Reader in Biotechnology, Kingston University

Who should attend?

Presidents, Chief Executive Officers, Chief Scientific Officers, Chief Technology Officers, Chief Operating Officers, Vice Presidents, Directors, Professors, Heads, Program Managers and Team Leaders in:

• Genomics
• Genome Sequencing
• Sequencing Technology
• Bioinformatics
• Computational Biology
• Medical Genetics
• Clinical Genetics
• Molecular Biology
• Molecular Medicine
• Oncology
• Clinical Research & Development
• Translational Medicine
• Stratified Medicine / Personalised Medicine
• Strategic Alliances
• Business Development